A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer

被引：0
|
作者：
Carlotta Defferrari
Sara Campora
Mauro D'Amico
Arnoldo Piccardo
Ennio Biscaldi
Daniela Rosselli
Ambra Pasa
Matteo Puntoni
Alberto Gozza
Alessandra Gennari
Silvia Zanardi
Rita Lionetto
Michela Bandelloni
Andrea DeCensi
机构：
[1] E.O. Ospedali Galliera,Unit of Medical Oncology
[2] E.O. Ospedali Galliera,Nuclear Medicine
[3] E.O. Ospedali Galliera,Radiology
[4] E.O. Ospedali Galliera,Gynecology
[5] E.O. Ospedali Galliera,Scientific Direction
[6] E.O. Ospedali Galliera,Health Direction
[7] E.O. Ospedali Galliera,Pharmacy
来源：
Journal of Ovarian Research | / 5卷
关键词：
Bevacizumab; Standardize Uptake Value; Epithelial Ovarian Cancer; Diabetic Macular Edema; Weekly Paclitaxel;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Long-term survival with bevacizumab in heavily pretreated and platinum-resistant mucinous ovarian cancer: A case report
    Tarumi, Yosuke
    Mori, Taisuke
    Matsushima, Hiroshi
    Kokabu, Tetsuya
    Tsuchiya, Hiroshi
    Kitawaki, Jo
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2018, 44 (02) : 347 - 351
  • [42] Bevacizumab toxicity in heavily pre-treated recurrent epithelial ovarian cancer
    Martin, I.
    Urban, R.
    Goff, B.
    GYNECOLOGIC ONCOLOGY, 2015, 139 (01) : 197 - 197
  • [43] Phase II trial of irinotecan plus bevacizumab for heavily pretreated recurrent ovarian cancer.
    Jain, Salvia Sanjay
    Makeyev, Yan G.
    Muggia, Franco
    Speyer, James L.
    Curtin, John Patrick
    Blank, Stephanie V.
    Boyd, Leslie R.
    Pothuri, Bhavana
    Fishman, David
    Li, Xiaochun
    Goldberg, Judith D.
    Tiersten, Amy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] Treatment with Cetuximab, Bevacizumab and Irinotecan in Heavily Pretreated Patients with Metastasized Colorectal Cancer
    Halama, Niels
    Herrmann, Christina
    Jaeger, Dirk
    Herrmann, Thomas
    ANTICANCER RESEARCH, 2008, 28 (6B) : 4111 - 4115
  • [45] Positive experience of intraperitoneal chemotherapy followed by intravenous chemotherapy in heavily pretreated patients with suboptimal residual ovarian cancer and primary peritoneal cancer
    Nicoletto, Maria Ornella
    Palma, Maurizia Dalla
    Donach, Martin E.
    Gusella, Milena
    Cappetta, Alessandro
    Shams, Malihe
    Marchet, Aberto
    Nardin, Margherita
    Pintacuda, Giovanna
    Di Maggio, Antonio
    Marchesi, Maddalena
    Carli, Paolo
    Fiduccia, Pasquale
    Artioli, Grazia
    Nitti, Donato
    TUMORI JOURNAL, 2010, 96 (06): : 918 - 925
  • [46] Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer
    Adam, Jean-Philippe
    Boumedien, Feriel
    Letarte, Nathalie
    Provencher, Diane
    GYNECOLOGIC ONCOLOGY, 2017, 147 (01) : 47 - 53
  • [47] Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer
    Watanabe, Yoh
    Etoh, Tomomaro
    Koike, Eiji
    Mizuno, Yoshiaki
    Wang, Wei-Min
    Hoshiai, Hiroshi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2010, 15 (05) : 468 - 471
  • [48] Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer
    Yoh Watanabe
    Tomomaro Etoh
    Eiji Koike
    Yoshiaki Mizuno
    Wei-Min Wang
    Hiroshi Hoshiai
    International Journal of Clinical Oncology, 2010, 15 : 468 - 471
  • [49] Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients
    Rodriguez-Freixinos, V.
    Farinas-Madrid, L.
    Gil-Martin, M.
    Barretina-Ginesta, P.
    Romeo, M.
    Villacampa, G.
    Pardo, B.
    Ahmed, H.
    Recalde, S.
    Piulats, J. M.
    Gomez-Plaza, M. C.
    Gil-Moreno, A.
    Sala, E.
    Martinez-Roman, S.
    Ponce, J.
    Melendez, C.
    Carballas, E.
    Dientsmann, R.
    Oaknin, A.
    GYNECOLOGIC ONCOLOGY, 2019, 152 (02) : 270 - 277
  • [50] Topotecan as single agent or in combination with carboplatin in pretreated and heavily pretreated patients with advanced ovarian cancer
    Martoni, A
    Pelusi, G
    De Jaco, P
    Taroni, B
    Cacciari, N
    Angelelli, B
    Marino, A
    Zamagni, C
    7TH BIENNIAL MEETING OF THE INTERNATIONAL GYNECOLOGIC CANCER SOCIETY, 1999, : 253 - 256
12345